GSK agrees to support manufacture of 60 million doses of Novavax’ COVID-19 vaccine candidate NVX-CoV2373 for use in UK

GSK has agreed to provide fill and finish manufacturing capacity at its Barnard Castle facility, starting as early as May 2021. The protein antigen component of the vaccine is produced by Novavax’ manufacturing partner FUJIFILM Diosynth Biotechnologies at its site in Billingham.

Source:

PharmaTimes